The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has ...

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that the UK’s National Institute for Health and Care Excellence (NICE ...

Basel, October 23, 2013 - Alcon, the global leader in eye care, and second largest division of Novartis, is pleased that the National Institute for Health and Care Excellence (NICE) has recommended ...

BRUSSELS (Reuters) - Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of ...

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for ...

JETREA (ocriplasmin) 2.5mg/mL intravitreal injection by ThromboGenics The FDA has approved Jetrea (ocriplasmin; ThromboGeneics) for the treatment of symptomatic vitreomacular adhesion (VMA), a ...

ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Denmark and Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug ...

Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole Pivotal data showed Jetrea significantly resolved ...

Alcon, a division of Novartis, acquired the rights to commercialize JETREA® outside the United States in March 2012. It launched the drug in the UK, its first European market, in April, followed by ...

ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...